{"id":59606,"date":"2025-01-06T05:41:03","date_gmt":"2025-01-06T05:41:03","guid":{"rendered":"https:\/?p=59606"},"modified":"2025-01-06T05:41:03","modified_gmt":"2025-01-06T05:41:03","slug":"neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/","title":{"rendered":"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential"},"content":{"rendered":"<h2>Neumora Therapeutics, Inc. (NMRA)<\/h2>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/NMRA#\">Neumora Therapeutics, Inc.<\/a> has caught the attention of analysts, who have rated the stock as a <strong>&#8220;Strong Buy&#8221;<\/strong> with a remarkable upside potential of <strong>+1,023.71%<\/strong>. The <strong>average analyst target price<\/strong> for the stock over the next 12 months is <strong>USD 24.38<\/strong>, based on forecasts from four analysts.<\/p>\n<h3>Current Performance<\/h3>\n<p>At its last closing price of <strong>USD 2.17<\/strong>, Neumora Therapeutics\u2019 stock has faced significant downward pressure:<\/p>\n<ul>\n<li><strong>Weekly Change:<\/strong> -80.85%<\/li>\n<li><strong>Monthly Change:<\/strong> -77.79%<\/li>\n<li><strong>Yearly Change:<\/strong> -86.39%<\/li>\n<\/ul>\n<p>These steep declines underscore the challenges the company faces but also highlight its potential as a high-risk, high-reward investment.<\/p>\n<h3>Analyst Sentiment<\/h3>\n<p>Despite the recent performance, the consensus among analysts is overwhelmingly bullish:<\/p>\n<ul>\n<li><strong>Average Analyst Rating:<\/strong> Strong Buy<\/li>\n<li><strong>Target Price:<\/strong> USD 24.38, reflecting confidence in a significant rebound.<\/li>\n<\/ul>\n<h3>Stock Target Advisor Analysis<\/h3>\n<p>Stock Target Advisor takes a more cautious stance, rating the stock as <strong>Bearish<\/strong> due to:<\/p>\n<ul>\n<li><strong>2 Positive Signals:<\/strong> Likely reflecting strengths such as pipeline potential or financial backing.<\/li>\n<li><strong>6 Negative Signals:<\/strong> Highlighting risks, such as recent performance trends or operational challenges.<\/li>\n<\/ul>\n<h3>Stock Analysis Based on Stock Target Advisor&#8217;s Composite Scorecard<\/h3>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor&#8217;s<\/a> analysis is a balanced approach that highlights both strengths and weaknesses of the stock based on key evaluation criteria. Below is a detailed examination based on their findings:<\/p>\n<hr \/>\n<h3><strong>What to Like:<\/strong><\/h3>\n<ol>\n<li><strong>Low Volatility<\/strong>\n<ul>\n<li><strong>Pros:<\/strong> The stock demonstrates stable and consistent annual returns compared to its sector peers, ranking in the top quartile for stability over a 12-month holding period.<\/li>\n<li><strong>Consideration:<\/strong> While stability is generally positive, it may limit potential upside, making the stock less attractive to aggressive growth-seeking investors.<\/li>\n<\/ul>\n<\/li>\n<li><strong>High Market Capitalization<\/strong>\n<ul>\n<li><strong>Pros:<\/strong> As one of the largest entities in its sector, the stock is in the top quartile for market cap. Large-cap stocks are often more stable and resilient, especially during market downturns.<\/li>\n<li><strong>Consideration:<\/strong> Stability in large-cap stocks may come at the expense of higher growth rates, especially in mature markets.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<hr \/>\n<h3><strong>What Not to Like:<\/strong><\/h3>\n<ol>\n<li><strong>Overpriced Compared to Book Value<\/strong>\n<ul>\n<li><strong>Concern:<\/strong> The stock&#8217;s price-to-book value ratio is significantly higher than its sector median, indicating it may be overvalued relative to its peers.<\/li>\n<li><strong>Implication:<\/strong> This could make the stock less attractive for value-oriented investors or those seeking undervalued opportunities.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Below Median Dividend Returns<\/strong>\n<ul>\n<li><strong>Concern:<\/strong> Over the past five years, the stock\u2019s income yield has been below its peers\u2019 median.<\/li>\n<li><strong>Implication:<\/strong> For income-focused investors, this stock might not be a preferred choice.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Poor Risk-Adjusted Returns<\/strong>\n<ul>\n<li><strong>Concern:<\/strong> The stock delivers below-median risk-adjusted returns compared to peers. Even if it occasionally outperforms, the returns are unpredictable.<\/li>\n<li><strong>Implication:<\/strong> This increases the risk for investors who prioritize consistent performance and a favorable risk-reward profile.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Negative Cash Flow<\/strong>\n<ul>\n<li><strong>Concern:<\/strong> The company has reported negative total cash flow in the most recent four quarters.<\/li>\n<li><strong>Implication:<\/strong> This could signal financial strain or significant investments that have yet to yield returns.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Negative Free Cash Flow<\/strong>\n<ul>\n<li><strong>Concern:<\/strong> Similar to cash flow, the company\u2019s negative free cash flow indicates it is not generating enough funds after operating expenses and capital expenditures.<\/li>\n<li><strong>Implication:<\/strong> This might impact the company\u2019s ability to reinvest, pay dividends, or reduce debt.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Low Earnings Growth<\/strong>\n<ul>\n<li><strong>Concern:<\/strong> Over the last five years, the company\u2019s earnings growth has been below the sector median.<\/li>\n<li><strong>Implication:<\/strong> This may raise concerns about the company&#8217;s ability to grow its profitability and deliver shareholder value over time.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<hr \/>\n<h3><strong>Overall Assessment<\/strong><\/h3>\n<ul>\n<li><strong>Strengths:<\/strong> The stock&#8217;s low volatility and high market cap make it an attractive option for conservative investors seeking stability.<\/li>\n<li><strong>Weaknesses:<\/strong> Overvaluation, poor risk-adjusted returns, negative cash flow, and low earnings growth highlight significant challenges. These issues may deter growth-focused or value investors.<\/li>\n<\/ul>\n<p><b>Considerations:<\/b><\/p>\n<ul>\n<li><strong>For Risk-Averse Investors:<\/strong> This stock could be a reasonable choice if stability is a top priority.<\/li>\n<li><strong>For Growth\/Value Investors:<\/strong> The negative cash flow, weak earnings growth, and overvaluation suggest this stock may not align well with your investment strategy.<\/li>\n<\/ul>\n<h3>Investment Outlook<\/h3>\n<p>Neumora Therapeutics presents an intriguing case for investors. The <strong>1,000% upside projection<\/strong> suggests substantial long-term growth potential, but the stock&#8217;s recent volatility and bearish signals warrant caution. This opportunity may appeal most to investors with a high risk tolerance and confidence in the company\u2019s ability to navigate current challenges and capitalize on its potential.<\/p>\n<p><strong>Disclaimer:<\/strong> As with all investments, thorough due diligence is essential. Consult a financial advisor to determine whether this stock aligns with your investment goals and risk profile.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neumora Therapeutics, Inc. (NMRA) Neumora Therapeutics, Inc. has caught the attention of analysts, who have rated the stock as a &#8220;Strong Buy&#8221; with a remarkable&#8230;<\/p>\n","protected":false},"author":3,"featured_media":59610,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-59606","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-blog","post_format-post-format-image"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential\" \/>\n<meta property=\"og:description\" content=\"Neumora Therapeutics, Inc. (NMRA) Neumora Therapeutics, Inc. has caught the attention of analysts, who have rated the stock as a &#8220;Strong Buy&#8221; with a remarkable...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-06T05:41:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/Neumora.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1277\" \/>\n\t<meta property=\"og:image:height\" content=\"315\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential\",\"datePublished\":\"2025-01-06T05:41:03+00:00\",\"dateModified\":\"2025-01-06T05:41:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/\"},\"wordCount\":718,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/\",\"name\":\"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-01-06T05:41:03+00:00\",\"dateModified\":\"2025-01-06T05:41:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/","og_locale":"en_US","og_type":"article","og_title":"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential","og_description":"Neumora Therapeutics, Inc. (NMRA) Neumora Therapeutics, Inc. has caught the attention of analysts, who have rated the stock as a &#8220;Strong Buy&#8221; with a remarkable...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-01-06T05:41:03+00:00","og_image":[{"width":1277,"height":315,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/Neumora.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential","datePublished":"2025-01-06T05:41:03+00:00","dateModified":"2025-01-06T05:41:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/"},"wordCount":718,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/","name":"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-01-06T05:41:03+00:00","dateModified":"2025-01-06T05:41:03+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/neumora-therapeutics-inc-nmra-strong-buy-with-1000-upside-potential\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/59606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=59606"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/59606\/revisions"}],"predecessor-version":[{"id":59611,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/59606\/revisions\/59611"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/59610"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=59606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=59606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=59606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}